Pharma BD Deal Intelligence

Lonza Group AG / Capsugel S.A. (KKR portfolio)

2016 · Acquisition/Merger · $5.5B · Complete

WRONG BY 36 POINTS

Lonza's $5.5B Capsugel bet integrated well early but was fully unwound nine years later — sold to Lone Star for $3B with a CHF 1.3B writedown as Lonza reversed course to become a "pure-play CDMO."

Full analysis, sources & comparables →

The coverage arc

Dec 15, 2016 BioPharma Dive Bullish

BioPharma Dive characterized the $5.5B Capsugel buy as Lonza moving to build an integrated solutions provider spanning APIs through finished dosage forms,…

Aug 29, 2017 FiercePharma Bullish

FiercePharma framed the Lonza-Capsugel and Thermo-Patheon deals together as $12.7B of M&A 'rapidly transforming' the CDMO industry into a smaller set of scaled…

Feb 13, 2026 FiercePharma Bearish

Lonza divested the legacy Capsugel capsules and health ingredients business to Lone Star for ~$3B to become a pure-play biologics CDMO — a retrospective signal…

Source summaries from our enrichment pipeline; follow links for originals.

All 5 sources with sentiment breakdown →

Lonza Group agreed to acquire Capsugel from KKR for $5.5B in cash, including refinancing of ~$2B Capsugel debt. EV/EBITDA multiple ~15.1x. Strategic intent: create leading integrated solutions provider in pharma and consumer healthcare/nutrition. Expected ~CHF 30M operating synergies plus ~CHF 15M tax synergies. Completed July 6, 2017.

Did it work? Outcome assessment

Lonza's $5.5B Capsugel bet integrated well early but was fully unwound nine years later — sold to Lone Star for $3B with a CHF 1.3B writedown as Lonza reversed course to become a "pure-play CDMO."

Strategic verdict
Failed to Achieve
Financial impact
Accretive
Pipeline outcome
Assets Advanced

Key facts

Related deals — scored

DealYearValueOutcome
Lonza Group AG / Capsugel S.A. (KKR portfolio) (this deal)2016$5.5B39
Lonza Group AG / Cambrex Bioproducts and Biopharma businesses2006$460M83
Lonza Group AG / Capsugel S.A.2016$5.5B44
Watson Pharmaceuticals (Actavis Inc.) / Actavis plc2012$5.9B97
Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital)2013$1.3B91
Stryker Corporation / MAKO Surgical Corp.2013$1.6B91
Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc.2016$17.6B91

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →